Spotlight on ranolazine in chronic stable angina pectoris

American Journal of Cardiovascular Drugs

Volumn 6, Issue 5, 2006, Pages 357-359

  Siddiqui, M Asif A ^a   Keam, Susan J ^b  

^a ADIS INTERNATIONAL INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANTIANGINA PECTORIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DILTIAZEM; KETOCONAZOLE; NITRATE; RANOLAZINE;

ARTICLE; ASTHENIA; CHRONIC DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG RELEASE; DRUG TOLERABILITY; EXERCISE TOLERANCE; HEART FAILURE; HUMAN; NAUSEA; NONHUMAN; PRIORITY JOURNAL; QT INTERVAL; STABLE ANGINA PECTORIS; TORSADE DES POINTES;

ADMINISTRATION, ORAL; ANGINA PECTORIS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; HUMANS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33751008639     PISSN: 11753277     EISSN: 11753277     Source Type: Journal    
DOI: 10.2165/00129784-200606050-00009     Document Type: Article

References (22)

1. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110 (8): 904-10
2. Belardinelli L, Antzelevitch C, Fraser H. Inhibition of late (sustained/persistent) sodium current: a potential drug target to reduce intracellular sodium-dependent calcium overload and its detrimental effects on cardiomyocyte function. Eur Heart J 2004; 6 (Suppl. I): 13-7
3. Brown CM, Clarke B, Dye A, et al. Pharmacological profile of ranolazine, a metabolic modulator active in ischemia [abstract]. Br J Pharmacol 1988; 93 Suppl.: 248P
4. Rousseau MF, Pouleur H, Cocco G, et al. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. Am J Cardiol 2005 Feb 1; 95 (3):311-6
5. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolazine,in chronic stable angina pectoris that is responsive to conventional antianginal agents: Ranolazine Study Group. Am J Cardiol 1999 Jul 1; 84 (1):46-50
6. Thadani U, Ezekowitz M, Fenney L, et al. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients withchronic stable angina pectoris: Ranolazine Study Group. Circulation 1994 Aug;90 (2): 726-34
7. Song Y, Shryock JC, Wu L, et al. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovascul Pharmacol 2004; 44 (2): 192-9
8. Wu L, Song Y, Shryock JC, et al. Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 2004; 310 (2):599-605
9. CV Therapeutics Inc. Product information (US): Ranexa™ (ranolazine) extended-release tablets 500mg; Jan 2006 [online]. Available from URL: http://ranexa.com/Ranexa.pdf [Accessed 2006 Feb 22]
10. Wolff AA. MARISA: monotherapy assessment of ranolazine in stable angina [abstract no. 1196-101]. J Am Coll Cardiol2000 Feb; 35 (Suppl. A): 408. Plus poster presented at the 49th Annual Scientific Session of the American College of Cardiology; 2000 Mar 12-15; Anaheim (CA)
11. Abdallah H, Jerling M. Effect of hepatic impairment on the multiple-dose pharmacokinetics of ranolazine sustained-release tablets. J Clin Pharmacol 2005 Jul; 45 (7): 802-9
12. Chu N, Sohoo D, Sun H-L, et al. In vitro metabolism of ranolazine [abstract no. 363]. Drug Metab Rev 2003; 35 Suppl. 2: 182
13. Jerling M, Abdallah H. Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine. Clin Pharmacol Ther 2005 Sep; 78 (3): 288-97
14. Jerling M, Huan BL, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005 Apr; 45 (4): 422-33
15. Chaitman BR. Measuring antianginal drug efficacy using exercise testing for chronic angina: improved exercise peformance with ranolazine, a pFOX inhibitor. Curr Probl Cardiol 2002 Dec; 27 (12): 527-55
16. Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol 2004 Apr 21; 43 (8): 1375-82
17. Chaitman BR, Pepine CJ, Parker JO, et al. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 2004 Jan 21; 291 (3): 309-16
18. Stone PH, Gratsianski NA, Blokhin A, et al. Anti-anginal efficacy of ranolazine when added to maximal therapy with conventional therapy: the Efficacy of Ranolazine In Chronic Angina trial [abstract no. 3491]. Circulation 2005; 112 (Suppl. 17): 748-9. Plus poster presented at the 78th annual scientific sessions of the American Heart Association; 2005 Nov 13-16; Dallas (TX)
19. Timmis AD, Chaitman BR, Crager M. Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes. Eur Heart J 2006; 27 (1): 42-8
20. White HD, Skettino S, Chaitman BR, et al. Anti-anginal efficacy of ranolazine addition to beta blocker or calcium antagonist therapy in patients with a history of heart failure [abstract no. 1746]. Circulation 2002 Nov 5; 106 (19 Suppl. II): 349-50
21. Chaitman BR, Skettino S, Parker JO, et al. Efficacy of ranolazine as add-on therapy for chronic angina in elderly patients [abstract no. 1649]. Circulation 2002 Nov 5; 106 (19 Suppl. II): 330
22. Koren MJ, Crager M, Sweeney M. Ranolazine safety and tolerability during long term treatment of stable angina [abstract no. 999-253]. J Am Coll Cardiol 2006; 47 (Suppl. 1): 218A